Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Tables)

v3.10.0.1
Net Loss Per Share (Tables)
9 Months Ended
Sep. 30, 2018
Earnings Per Share [Abstract]  
Schedule of Net Loss Per Share

The following table reconciles net loss to net loss attributable to Heat Biologics, Inc.:


 

 

Three Months Ended

September 30,

 

 

Nine Months Ended

September 30,

 

 

 

2018

 

2017

 

 

2018

 

 

2017

 

Net loss

 

$

(3,923,586

)

$

(2,504,178

)

 

$

(11,463,927

)

 

$

(9,053,987

)

Net loss: Non-controlling interest

 

 

(265,024

)

 

(203,371

)

 

 

(668,219

)

 

 

(344,328

)

Net loss attributable to Heat Biologics, Inc.

 

$

(3,658,562

)

$

(2,300,807

)

 

$

(10,795,708

)

 

$

(8,709,659

)

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

  

Weighted-average number of common shares used in net loss per share attributable to Heat Biologics, Inc.—basic and diluted

 

 

23,143,952

 

 

3,578,661

 

 

 

14,359,429

 

 

 

3,269,536

 

Net loss per share attributable to Heat Biologics, Inc.—basic and diluted

 

$

(0.16

)

$

(0.64

)

 

$

(0. 75

)

 

$

(2.66

)

Schedule of Potentially Dilutive Securities

The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:


 

 

For the Nine months Ended

September 30,

 

 

 

2018

 

2017

 

Outstanding stock options

 

 

465,406

 

 

267,355

 

Outstanding restricted stock units

 

 

61,144

 

 

29,138

 

Outstanding common stock warrants

 

 

4,430,730

 

 

310,397